GlaxoSmithKline Capital PLC Publication of Supplementary EMTN Prospectus (2515H)
23 November 2022 - 6:44PM
UK Regulatory
TIDMAG99 TIDMGSK
RNS Number : 2515H
GlaxoSmithKline Capital PLC
22 November 2022
Issued: 22 November 2022, London UK - LSE Announcement
GlaxoSmithKline Capital plc Publication of Supplement to the
Base Prospectus
GlaxoSmithKline Capital plc today announced that the following
supplement dated 22 November 2022 to the base prospectus dated 7
September 2022 (as supplemented by the prospectus supplement dated
3 November 2022 and by the prospectus supplement dated 18 November
2022) has been approved by the UK Listing Authority and is
available for viewing:
GSK plc, GlaxoSmithKline Capital plc, GSK Capital B.V. and GSK
Capital K.K. GBP20,000,000,000 Euro Medium Term Note Programme
Copies of the supplement to the base prospectus and the
documents incorporated by reference within it have been submitted
to the National Storage Mechanism and will shortly be available for
inspection at and can be downloaded from:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
For further information, please contact:
GSK plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
Enquiries:
UK Media enquiries: Tim Foley +44 (0) 20 8047
5564
(London)
European Analyst/Investor Nick Stone +44 (0) 7717 618
enquiries: 834
(London)
James Dodwell
+44 (0) 7881 269
066
(London)
BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENT TO THE BASE
PROSPECTUS
Please note that the information contained in the supplement to
the base prospectus may be addressed to and/or targeted at persons
who are residents of particular countries (specified in the base
prospectus) only and is not intended for use and should not be
relied upon by any person outside these countries and/or to whom
the offer contained in the supplement to the base prospectus is not
addressed. Prior to relying on the information contained in the
supplement to the base prospectus you must ascertain from the
supplement to the base p rospectus whether or not you are part of
the intended addressees of the information contained therein.
Your right to access this service is conditional upon complying
with the above
About GSK
GSK is a global biopharma company with a purpose to unite
science, technology, and talent to get ahead of disease together.
Find out more at gsk.com/company
GSK plc
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PSPFEWFDEEESEIF
(END) Dow Jones Newswires
November 22, 2022 11:00 ET (16:00 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024